Udai P. Singh, Ph.D.
Research Associate Professor
& Assistant Director of Flow Cytometry &
Cell Sorting Facility
M.S., 1987 Gorakhpur University Gorakhpur, India
Ph.D., 1992 Banaras Hindu University Varanasi, India
Office: (803) 216-3423
Fax: (803) 803-216-3413
My primary research interest includes in the area of immunology, mucosal inflammation, chemokines, immunotherapy and complimentary and alternative medicine. Inflammatory bowel disease (IBD) is a gastrointestinal disease of chronic inflammatory condition and the causes of human IBD remain unknown. We have shown that anti-CXCL10 Ab treatment abrogates spontaneous colitis. Currently, I am working on to understand the steps during CXCL10 mediated cellular and molecular mechanism of IBD abrogation and host immune response during the progression of IBD. This will help to better understand the pathogenesis of IBD and other inflammatory conditions. This work will contribute to a better understanding of autoimmune disease pathogenesis and the development of vaccines for inflammation therapeutics in general.
Currently, I am working on intervention and prevention strategies against interstitial cystitis (IC), which is a chronic, relapsing and severely debilitating disease of the urinary bladder. Compounding these problems is the lack of blood or urine tests and consistently effective treatments for IC. We show the increase in CXCR3 ligands in the serum of IC patient as compare to normal healthy donors. We show for the first time that, CXCL10, CXCL9, and CXCL11 are significantly up regulated both systemic as well mucosal in IC patients, compared to normal healthy donors. These studies have important implications for the design, assessment, and implementation of effective IC diagnosis, intervention and prevention strategies.
I am also working on another project to examine the effects of resveratrol on experimental murine model of colitis. We have shown that resveratrol protects against chronic and dextran sodium sulphate (DSS) induced colitis by inducing myeloid derived suppressor cells (MDSCs), down regulating mucosal and systemic effectors and CD4+T cells that express CXCR3+ expression. I wish to continue my work in the field of mucosal immunology, inflammation using alternative medicine as effective treatment for various autoimmune diseases and inflammation in general.
- Singh, U.P*., Narendra P. Singh, Brandon Busbee, Guan, H., Balwan Singh, Robert L. Price, Dennis D. Taub,* Manoj K. Mishra, Mitzi Nagarkatti, & Prakash S. Nagarkatti. (2012). Alternative medicines as emerging therapies for inflammatory bowel diseases. International Reviews of Immunology. 31:1-19.
- Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price, Mitzi Nagarkatti, and Prakash S. Nagarkatti. (2012). Role of resveratrol-induced CD11b+ Gr-1+ myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3+ T cells and amelioration of chronic colitis in IL-10-/- mice. Brain, Behavior and Immunity. 26(1): 72-82.
- Singh, U.P.*, Narendra P. Singh*, Balwan Singh, Robert L Price, Mitzi Nagarkatti, and Prakash S. Nagarkatti. (2011). Activation of Aryl Hydrocarbon Receptor Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 genes and Amelioration of Experimental Colitis. PLoS ONE. 6(8): e23522
- Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price, Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010). Resveratrol (trans-3, 5, 4'-trihydroxystilbene) induces SIRT1 and down-regulates NF-kB activation to abrogate DSS-induced colitis. J. Pharmacology & Exp. Therapeutics. 332(3): 829-839.
- Singh, U.P., Narendra P. Singh, Balwan Singh, Mishra Manoj, Mitzi Nagarkatti, Prakash S. Nagarkatti and Singh SR (2010). Stem cells as potential therapeutic targets for Inflammatory Bowel Disease. Frontiers in Biosciences S. (2): 993-1008.
- Lorne J. Hofseth, Singh, U.P., Narendra P. Singh, Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010). Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2(4): 183-184.
- Singh U.P., Singh, S., Singh, R., Cong, Y., Taub, D.D. and J.W. Lillard, Jr. (2008). Chronic colitis and CXCL10-producing mucosal T helper, NK and NKT cells in IL10-/- mice can be abrogated by CXCL10 blockade. Journal of Interferon & Cytokine Research. 28(1): 31-43.
- Singh U.P., Singh S, Chandrasekar Venkataraman and James W. Lillard, Jr. (2007). CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. Endocrine, Metabolic & Immune Disorder: Drug Target. 7(2): 111-123.
- Singh U.P., Singh S, Singh R, Frederick D. Quinn, Morris E. Potter & James W. Lillard, Jr. (2007). Influence of Mycobacterium avium paratuberculosis on colitis development and specifics immune responses during disease. Infection and Immunity. 75 (8): 3722-3278.
- Palaniappan R, Singh S, Singh U.P., Sakthivel SK, Ades EW, Briles DE, Hollingshead SK, Paton JC, Sampson JS, and J.W. Lillard, Jr. (2005). Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of Pneumococcal Carriage. Infection Immunity. 73(2): 1006-13.
- Ravichandran Palaniappan, Shailesh Singh, Singh U.P., Edwin W. Ades, David E. Briles, Susan K. Hollingshead, Walter Royal, III, Jacquelyn S. Sampson, Jonathan K. Stiles, Dennis D. Taub, and James W. Lillard, Jr. (2006). CCL5 Modulates Pneumococcal Immunity and Carriage.Journal of Immunology. 176: 2346-2356.
- Singh U.P., S. Singh, R. Palaniappan, D.D. Taub, and J.W. Lillard, Jr. (2004). vMIP-II versus I-309 effects on adaptive immunity. Journal of Immunology. 173:5509-5516.
- Singh U.P., Singh S., Boyaka, P.N., McGhee, J.R., and Lillard, J.W. Jr. (2004).Granulocyte chemotactic protein-2 mediates adaptive immunity through CXCR1 interactions and CD28/B7 up regulation. Journal of Leukocyte Biology.76:1240-1247.
- S. Singh, U.P. Singh, W.E. Grizzle, and J.W. Lillard, Jr. (2004). CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Laboratory Investigation. 84: 1666-1676.
- Lillard, Jr., J. W., U.P. Singh, P.N. Boyaka, S. Singh, D.D. Taub and J.R. McGhee (2003). MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood.101: 807-814.
- Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003). Inhibition of IP-10 abrogates colitis in IL-10-/- mice. Journal of Immunology. 171:1401-1406.
- Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003). Interferon-inducible chemokines differentially mediate adaptive immunity and colitis. Journal of Interferon & Cytokine Research. 23(10): 591-600.